Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for treating vascular disorders

A vascular and disease technology, applied in the field of medical science, can solve problems beyond the physiological toxicity range of r-aPC

Inactive Publication Date: 2000-05-10
ELI LILLY & CO
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, Applicants found that these dose levels were significantly outside the physiological toxicity range of r-aPC
For example, preclinical toxicology studies in non-human primates have shown that the safe value of r-aPC for a 96-hour infusion is limited to a maximum dose of approximately 0.05 mg / kg / hour

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0032] human protein C

[0033] Recombinant human protein C (rHPC) is produced in human kidney 293 cells by techniques well known to those skilled in the art, see, eg, US Patent 4,981,952 to Yan, the entire teaching of which is incorporated herein by reference. The gene encoding human protein C is disclosed and claimed in US Patent 4,775,624 to Bang et al., the entire teachings of which are incorporated herein by reference. The plasmid used to express human protein C in 293 cells is the plasmid pLPC disclosed in US Patent 4,992,373 to Bang et al., the entire teaching of which is incorporated herein by reference. The construction of plasmid pLPC is also described in European Patent 0445939 and Grinnell et al., 1987, Bio / Technology 5: 1189-1192, the entire teachings of which are incorporated herein by reference. Briefly, this plasmid was transfected into 293 cells, stable transformants were identified, subcultured and grown in serum-free medium. After fer...

preparation example 2

[0038] Activation of recombinant human protein C

[0039] Thrombin was coupled to activated CH-Sepharose (Sepharose) 4B (Pharmacia) at pH 7.5 in the presence of 50 mM HEPES at 4°C. The coupling reaction was carried out on the resin already packed into the column, using about 5000 units of thrombin / ml resin. The thrombin solution was circulated through the column for about 3 hours before adding MEA at a concentration of 0.6 ml / l of circulating solution. The solution containing MEA was recirculated for 10-12 hours to ensure complete blocking of unreacted amine on the resin. After blocking, the thrombin-coupled resin was washed with 10 times volume of 1M NaCl, 20mM Tris, pH 6.5 to remove non-specifically bound proteins, and used for activation reaction after equilibrating in activation buffer.

[0040] Purified rHPCs were formulated in 5 mM EDTA (to chelate any residual calcium ions) and diluted to a concentration of 2 mg / ml with 20 mM Tris, pH 7.4 or 20 mM T...

Embodiment 1

[0046] Human plasma concentration of aPC

[0047] Within 24 hours, 6 patients received 1 mg / m 2 / hour or about 0.024mg / kg / hour received aPC intravenous infusion. The aPC used was a lyophilized preparation containing 10 mg aPC, 5 mM Tris acetate buffer and 100 mM NaCl, redissolved with 2 ml of water and adjusted to pH 6.5.

[0048] Plasma concentrations of aPC were measured using an immunocapture-amidolytic assay. Blood was collected in the presence of citrate anticoagulant and benzamidine, a reversible inhibitor of aPC. The enzyme was captured from plasma by using an aPC-specific mouse monoclonal antibody, C3, immobilized on a microplate. This inhibitor was removed by washing and the amidolytic activity of aPC was detected with an oligopeptide chromogenic substrate. After incubation at 37°C for 16-20 hours, the absorbance was measured at 405 nm, and the data were analyzed using a weighted linear curve fitting algorithm. The concentration of aPC estima...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Extinction coefficientaaaaaaaaaa
Login to View More

Abstract

The use of activated protein C for the manufacture of a medicament for the treatment of vascular occlusive and thromboembolic disorders at a dose of about 0.01mg / kg / hr to about 0.05mg / kg / hr.

Description

field of invention [0001] The present invention relates to medical science, and in particular to the treatment of vascular diseases with activated protein C. Background of the invention [0002] Protein C is a serine protease and natural anticoagulant that plays an important role in the regulation of homeostasis by inactivating factors Va and VIIIa in the coagulation cascade. Human protein C is mainly synthesized in the liver in the form of a single polypeptide consisting of 461 amino acids. This precursor molecule undergoes multiple post-translational modifications, including 1) cleavage of the signal sequence containing 42 amino acids; 2) proteolytic removal of the lysine residue at position 155 of the single-chain zymogen, and proteolytic removal of the lysine residue at position 156 Arginine residues are removed to prepare molecules in double-chain form (ie, the light chain of 155 amino acid residues is connected to the heavy chain of 262 amino acid residues containing ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/48A61K38/00A61P7/02A61P9/00A61P43/00C12N9/64
CPCA61K38/00C12N9/6464C12Y304/21069A61P43/00A61P7/02A61P9/00A61P9/10
Inventor B·W·格林内利D·C·霍维C·V·杰克森
Owner ELI LILLY & CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com